GSK VS ZTS Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend

Performance

GSK
10/100

GSK returned 3.98% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

ZTS
100/100

ZTS returned 16.56% in the last 12 months. Based on SPY's performance of -13.45%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

GSK
63/100

4 analysts offer 12-month price targets for GSK. Together, they have an average target of 0, the most optimistic target put GSK at 0 within 12-months and the most pessimistic has GSK at 0.

ZTS
75/100

21 analysts offer 12-month price targets for ZTS. Together, they have an average target of 0, the most optimistic target put ZTS at 0 within 12-months and the most pessimistic has ZTS at 0.

Technicals

GSK
10/100

GSK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

ZTS
82/100

ZTS receives a 82 of 100 based on 14 indicators. 11 are bullish, 2 are bearish.

Earnings

GSK
66/100

GSK has missed earnings 3 times in the last 20 quarters.

ZTS
53/100

ZTS has missed earnings 2 times in the last 20 quarters.

Profit

GSK
72/100

Out of the last 20 quarters, GSK has had 20 profitable quarters and has increased their profits year over year on 7 of them.

ZTS
78/100

Out of the last 20 quarters, ZTS has had 19 profitable quarters and has increased their profits year over year on 11 of them.

Volatility

GSK
56/100

GSK has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.

ZTS
50/100

ZTS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

Dividend

GSK

"Dividend" not found for GSK

ZTS
35/100

ZTS's most recent dividend was $0.12 per share, based on a share price of $174.62. It was a payout ratio of 17.39% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

GSK plc American Depositary Shares (Each representing two Ordinary Shares) Summary

New York Stock Exchange / GSK
Healthcare
Drug Manufacturers - General
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

ZOETIS INC. Summary

New York Stock Exchange / ZTS
Healthcare
Drug Manufacturers - Specialty & Generic
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.